Peptide Vaccines Targeting CDC25B and COX2 Prevent Colon Cancer in Multiple Mouse Models | Research

The takeaway

Multi-epitope peptide vaccines targeting CDC25B and COX2 consistently suppressed colon tumor development across three mouse models, with 50% of vaccinated mice remaining tumor-free in the prevention setting.

50% of mice tumor-free
In the AOM colon cancer prevention model with CDC25B or COX2 peptide vaccination

What the researchers found

CDC25B and COX2 peptide vaccines consistently prevented colon cancer across three mouse models: transplanted tumor, AOM-induced, and APC Min genetic models, with 50% tumor-free rates in the AOM prevention setting.

Why it matters

Colorectal cancer is the third most common cancer worldwide. A preventive vaccine could dramatically reduce disease burden, especially for high-risk individuals with family history or genetic predisposition.

The numbers in context

CDC25B + COX2 effective; 50% tumor-free (AOM); MC38 inhibited (p<0.0001); APC Min fewer tumors (CDC25B p=0.01, COX2 p=0.02); RCAS1 and FASCIN1 ineffective

How the study worked

ELISA for serum antibodies in cancer patients. Human T-cell epitope prediction and validation by ELISPOT. Mouse immunization with homologous peptides. Three tumor models: MC38 syngeneic tumor challenge, AOM chemical carcinogen, and APC Min transgenic mice.

Who was studied

FVB/nJ mice with MC38 tumors, AOM-treated mice, and APC Min transgenic mice

What this study cannot tell us

Mouse study — immune responses and tumor biology differ from humans. Homologous but not identical peptides between mouse and human. RCAS1 vaccination showed no anti-tumor effect despite immunogenicity. Long-term prevention not assessed.

How to read the evidence

Comprehensive preclinical study with human immunogenicity validation and three complementary mouse models. Strong preclinical evidence for cancer prevention vaccine development.

When this study was published

Published in 2021, contributing to the growing field of cancer prevention vaccines.

The bigger picture

Cancer prevention vaccines represent a paradigm shift from treating cancer after it develops to preventing it altogether. Success in preventing chemically-induced and genetically-driven colon cancers in mice suggests these peptide vaccines could potentially protect high-risk humans from developing colorectal cancer.

Questions still open

Would these vaccines work as prevention in humans with hereditary colon cancer syndromes?
Could CDC25B and COX2 peptide vaccines be combined with checkpoint inhibitors?
Why did RCAS1 fail despite generating immune responses?

Common questions

Could a vaccine prevent colon cancer?

This study shows it's possible in mice. Peptide vaccines targeting CDC25B and COX2 proteins prevented colon tumors from developing in both chemically-induced and genetic cancer models, with half of vaccinated mice remaining completely cancer-free.

Who might benefit from a colon cancer prevention vaccine?

If these results translate to humans, people at high risk for colorectal cancer — such as those with Lynch syndrome, familial adenomatous polyposis, or strong family history — could potentially be vaccinated to reduce their cancer risk, similar to how HPV vaccines prevent cervical cancer.

Read the original research

Multi-Epitope-Based Vaccines for Colon Cancer Treatment and Prevention.

Frontiers in immunology, 12, 729809

View on PubMed ↗Publisher’s paper ↗

Citation

Corulli, Lauren R; Cecil, Denise L; Gad, Ekram; Koehnlein, Marlese; Coveler, Andrew L; Childs, Jennifer S; Lubet, Ronald A; Disis, Mary L. (2021). Multi-Epitope-Based Vaccines for Colon Cancer Treatment and Prevention.. Frontiers in immunology, 12, 729809. https://doi.org/10.3389/fimmu.2021.729809